Background: Sexual dysfunction is more common among patients with mental disorders compared to the general population. Despite this high occurrence, information regarding sexual dysfunction as well as their correlates in patients receiving care for mental disorders in developing countries is still sparse.

Aim: To determine the prevalence and correlates of sexual dysfunction among patients with mental disorders receiving care in a tertiary hospital in Southwest Nigeria.

Setting: This study was performed at the psychiatric outpatient clinic at the University College Hospital, Ibadan, Southwest Nigeria.

Methods: A cross-sectional study was conducted on a convenience sample of 238 adults aged 18-60 years. Socio-demographic and clinical information was obtained from all recruited patients. Sexual dysfunction was assessed using the International Index of Erectile Function questionnaire for men and the Female Sexual Function Index questionnaire for women. Questionnaires for measuring depression, medication adherence and autonomic medication side effects were also administered. Associations between sexual dysfunction and socio-demographic and clinical factors were explored.

Results: The prevalence rates of sexual dysfunction among male and female participants were 84.7% and 95.7%, respectively. In the multivariate analysis, employment status and autonomic side effects of psychotropic medications significantly predicted male sexual dysfunction, while religion and employment status were predictors of female sexual dysfunction.

Conclusion: Sexual dysfunction is very common among patients with mental disorders, with higher rates in female participants. There is a need for clinicians to consider routine screening for sexual dysfunction in psychiatric outpatients with a view of providing psychosocial interventions to improve patient's quality of life.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182448PMC
http://dx.doi.org/10.4102/sajpsychiatry.v27i0.1575DOI Listing

Publication Analysis

Top Keywords

sexual dysfunction
40
mental disorders
20
patients mental
16
sexual
12
dysfunction
10
prevalence correlates
8
correlates sexual
8
dysfunction patients
8
tertiary hospital
8
hospital southwest
8

Similar Publications

Who is a candidate at the initial presentation? Prediction of positive lateral lymph node and survival after dissection.

Tech Coloproctol

January 2025

Department of Colorectal Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodearo, Seochogu, Seoul, 06591, Korea.

Metastatic lateral pelvic lymph node (LPN) in rectal cancer has a significant clinical impact on the prognosis and treatment strategies. But there are still debates regarding prediction of lateral pelvic lymph node metastasis and its oncological impact. This review explores the evidence for predicting lateral pelvic lymph node metastasis and survival in locally advanced rectal cancer.

View Article and Find Full Text PDF

Female Sexual Health and Cancer.

Clin Obstet Gynecol

March 2025

Adult Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

As the majority of female cancer survivors can now expect to live long lives beyond cancer diagnosis and treatment, there is a growing need to address the significant late effects of treatment. Unfortunately, sexual health remains a primary concern that often goes unaddressed among female cancer survivors. Sexual dysfunction is one of the most common and distressing effects of treatment.

View Article and Find Full Text PDF

Pain that occurs during sexual activity is highly prevalent during a woman's lifetime, affecting ∼15% of women. The etiology of dyspareunia is multifactorial. Therefore, treatment must be individualized.

View Article and Find Full Text PDF

Novel Pharmacologic Treatments of Female Sexual Dysfunction.

Clin Obstet Gynecol

March 2025

Department of Psychiatry & Neurobehavioral Sciences.

This review evaluates pharmacologic treatments for female sexual dysfunction (FSD), focusing on hypoactive sexual desire disorder (HSDD). We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!